Positive results from Phase III trial of rexlemestrocel-L in patients with chronic heart failure

In the DREAM-HF trial in patients with chronic heart failure and reduced left ventricular ejection fraction (n=537), a single dose of rexlemestrocel-L was associated with a reduction in three-point MACE over a median of 30 months (20.6% v 30%; p=0.027).

Source:

Biospace Inc.